Characterizing opioid withdrawal during double-blind buprenorphine detoxification

Area of Science:

• Addiction Medicine
• Pharmacology
• Clinical Psychology

Background:

• Prescription opioid (PO) abuse is a significant public health concern in the U.S.
• Buprenorphine detoxification is a key treatment, but withdrawal patterns are not well-understood.

Purpose of the Study:

• To characterize the time course and severity of buprenorphine withdrawal.
• To compare withdrawal across different outpatient taper durations (1, 2, and 4 weeks).
• To identify predictors of withdrawal severity.

Main Methods:

• Secondary analysis of a randomized, placebo-controlled, double-blind trial.
• Included 28 adults with PO dependence undergoing buprenorphine detoxification.
• Assessed withdrawal using self-report, observer ratings, pupil diameter, and medication use.

Main Results:

• The 4-week taper group had mild, stable withdrawal; 1- and 2-week groups showed sharp withdrawal increases post-taper.
• Shorter tapers led to greater withdrawal severity and sleep disruptions.
• Anticipated withdrawal severity at baseline was the strongest predictor of experienced withdrawal.

Conclusions:

• Findings inform clinicians about expected buprenorphine withdrawal patterns.
• Helps identify patients needing extra support during outpatient detoxification.
• Supports longer buprenorphine taper durations for smoother withdrawal.